Mass index; FBG: fasting blood glucose; eGFR: estimated glomerular filtration rate; ALT: alanine transaminase; AST: aspartate transaminase; CHD: coronary heart disease. One-way ANOVA and Kruskal-Wallis test were employed for statistical analyses.expression of platelet PAC-1 and CD62p. The statistical software package Stata 11.0 (Stata Corp. LP, USA) was utilized for the analysis.the groups. The lipid profiles of atorvastatin-treated sufferers are shown in Table 2. Whole blood flow cytometry The data showed elevated platelet surface expression of CD62p (P-selectin) and PAC-1 (GPIIb/IIIa) within the HNC group compared with the NOMC group (P=0.004 and P=0.014). In addition, the expressions of platelet markers CD62p and PAC-1 were higher inside the HLC group than within the HNC group (P=0.004 and P=0.026; Table 3 and Figure 1). The platelet activation markers CD62p and PAC-1 decreased substantially right after atorvastatin treatment (Table three). The parameter baseline of two months was obtained to analyzeResultsCharacteristics of participants A total of 48 individuals with high levels of LDL-C were recruited: 25 Caspase 9 custom synthesis patients within the HNC group and 23 sufferers in the HLC group. The NOMC group consisted of 35 healthful volunteers. The relevant biochemical and hematological benefits are reported in Table 1. There had been no differences in age, gender, body mass index, or cardiovascular danger aspects (hypertension, Nav1.4 custom synthesis diabetes mellitus, smoking history) betweenTable 2. Lipid profiles of atorvastatin-treated patients at baseline and soon after 1 and two months of remedy. TC (mM) Baseline HNC (n=25) HLC (n=23) 1 month HNC (n=25) HLC (n=23) two months HNC (n=25) HLC (n=23) NOMC (n=35) TG (mM) LDL-C (mM) HDL-C (mM)six.67 ?0.66 six.60 ?0.54 four.86 ?0.84### 4.64 ?0.92### 4.79 ?0.71### 4.78 ?0.46### four.12 ?0.1.69 ?0.29 1.66 ?0.42 1.39 ?0.47## 1.39 ?0.39# 1.75 ?0.46 1.60 ?0.36 1.64 ?0.four.41 ?0.20 4.47 ?0.22 two.53 ?0.80### 2.29 ?0.63### two.42 ?0.40### 2.60 ?0.41### 1.78 ?0.1.13 ?0.14 0.88 ?0.10nnn 1.11 ?0.23 0.91 ?0.20 1.00 ?0.19# 0.88 ?0.20 1.15 ?0.Information are reported as signifies D. TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HNC: high levels of LDL-C combined with regular levels of HDL-C; HLC: high levels of LDL-C combined with low levels of HDL-C; NOMC: normocholesterolemic. P,0.001 vs handle (NOMC); # P,0.05 vs baseline; ## P,0.01 vs baseline; ### P,0.001 vs baseline; nnn P,0.001 vs HNC. One-way ANOVA, Kruskal-Wallis test, group t-test, Wilcoxon’s test, paired t-tests and matched-pairs signed-rank tests had been utilised for statistical analyses.bjournal.brBraz J Med Biol Res 48(two)L.W. Chan et al.Table three. Parameters of platelet CD62p and PAC-1 among HNC and HLC patients and NOMC volunteers. Platelet CD62p ( ) HNC (n=25) Baseline 1 mo ATOR 2 mo ATOR Baseline-2 mo HLC (n=23) Baseline 1 mo ATOR two mo ATOR Baseline-2 mo NOMC (n=35) Platelet PAC-1 ( ) MPAG ( )1.62 1.53 0.88 0.74 two.60 1.19 1.51 1.04 0.?????????1.01 1.71 0.74## 1.12 1.19nn 1.43### 1.67##NS 1.92NS 0.4.21 three.57 1.36 two.85 five.90 four.03 two.33 three.57 2.?????????two.50 two.63 1.02### two.73 two.58n two.67# 1.57###n two.55NS two.31.54 29.61 26.85 4.70 37.15 28.21 26.18 ten.97 29.?????????15.12 17.46 ten.62 19.11 18.85 16.41 12.59# 21.59NS 17.HNC: high levels of LDL-C combined with normal levels of HDL-C; HLC: higher levels of LDL-C combined with low levels of HDL-C; NOMC: normocholesterolemic; mo: month; ATOR: atorvastatin; MPAG: maximal platelet aggregation. P,0.05 vs control; P,0.01 vs manage (NOMC); P,0.001 vs.